Vital NICE nod for Jazz’s Epidyolex
UK-wide therapy for patients who have seizures linked to tuberous sclerosis complex
Read Moreby John Pinching | Feb 1, 2023 | News | 0
UK-wide therapy for patients who have seizures linked to tuberous sclerosis complex
Read Moreby John Pinching | Sep 14, 2022 | News | 0
Therapy is for the treatment of spasticity due to multiple sclerosis
Read Moreby John Pinching | Jun 15, 2022 | News | 0
Jazz Pharmaceuticals and Redx announce that pan-RAF inhibitor will enter clinical development
Read Moreby John Pinching | Mar 25, 2022 | News | 0
The site in Kent will support the manufacture of regulatory approved cannabis-based medicines while also leveraging environmental practices
Read Moreby Selina McKee | Jun 16, 2020 | News | 0
The approval gives patients who relapse a new second-line option for the first time in nearly 20 years
Read Moreby Selina McKee | Sep 26, 2019 | News | 0
JZP-258 achieved primary and key secondary endpoints showing significant differences in weekly number of cataplexy attacks and Epworth Sleepiness Scale scores compared to placebo
Read Moreby Selina McKee | Nov 8, 2018 | News | 0
Jazz Pharmaceuticals’ chemotherapy Vyxeos has won the backing of the National Institute for Health and Care Excellence (NICE) for routine use on the NHS in England and Wales to treat certain acute myeloid leukaemias (AML).
Read Moreby Selina McKee | Aug 29, 2018 | News | 0
Dublin, Ireland-based Jazz Pharmaceuticals will be celebrating news of European approval of its leukaemia drug Vyxeos.
Read Moreby Selina McKee | Nov 6, 2017 | News | 0
Dublin, Ireland-based Jazz Pharmaceuticals’ Vyxeos is being given a speedy review in Europe as a treatment for certain types of high-risk acute myeloid leukemia (AML).
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
